Clinical trials: sponsored by Shanghai JMT-Bio Inc.
Valid MeSH Conditiongs
Evaluate the Safety and Tolerability of Multiple Doses of JMT206 Injection in Obese Participants
Use these resources to provide understandable information about this study to patients, families, and health care providers:
- Trial name
- NCT07840729
- Testing
- JMT206 injection, Semaglutide injection
- Where
- China
- Volunteers
- 90 people
- Sponsor
- Shanghai JMT-Bio Inc.
Hypercalcemia of Malignancy
A Clinical Trial to Assess the Efficacy and Safety of JMT103 in Patients With Refractory HCM
The purpose of this study is to determine the potential of JMT103 to treat hypercalcemia of malignancy in patients with elevated serum calcium who do not respond to recent treatment with intravenous bisphosphonates.
- Trial name
- NCT04198480
- Testing
- JMT103
- Where
- China
- Volunteers
- 4 people
- Sponsor
- Shanghai JMT-Bio Inc.
Unresectable Locally Advanced or Metastatic Melanoma, Unresectable Locally Advanced or Metastatic Urinary Tract Tumors
Phase I/II Clinical Study of JMT108 Injection for the Treatment of Advanced Malignant Melanoma and Urinary Tract Tumors
This is an open-label, multicenter Phase I/II clinical study conducted in participants with unresectable locally advanced or metastatic melanoma and urinary tract tumors, aiming to evaluate the safety, tolerability…
- Trial name
- NCT07280832
- Testing
- JMT108
- Where
- China
- Volunteers
- 500 people
- Sponsor
- Shanghai JMT-Bio Inc.
Early or Locally Advanced HER2-positive Breast Cancer
A Phase III Study of KN026 in Combination With HB1801 ± Carboplatin as Neoadjuvant Treatment for Early or Locally Advanced HER2-Positive Breast Cancer
This randomized, controlled, open-label, multicenter study will evaluate the safety and efficacy of KN026 in combination with HB1801 ± Carboplatin as neoadjuvant therapy in patients with early or locally advanced HER2-positive…
- Trial name
- Neo-Healer (NCT06747338)
- Testing
- KN026, HB1801, Pertuzumab
- Where
- China
- Volunteers
- 520 people
- Sponsor
- Shanghai JMT-Bio Inc.
Non Small Cell Lung Cancer, Pancreatic Cancer
A Study of JMT203 in Patients With Cancer Cachexia
A Phase Ia/II, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of JMT203 in Patients with Cancer Cachexia
- Conditions
- Non Small Cell Lung Cancer, Pancreatic Cancer, Cancer Cachexia, Colorectal Cancer Cachexia
- Trial name
- NCT06868849
- Testing
- JMT203 Injection
- Where
- China
- Volunteers
- 307 people
- Sponsor
- Shanghai JMT-Bio Inc.
HER2-positive Recurrent or Metastatic Breast Cancer
A Study of JSKN003 Versus Trastuzumab in Combination With Pertuzumab and Docetaxel as First-Line Treatment for HER2-Positive Recurrent or Metastatic Breast Cancer
This study is a randomized, controlled, open-label, multicenter, phase II superiority clinical trial. The planned study population consists of participants with HER2-positive recurrent or metastatic breast cancer who have not…
- Trial name
- NCT07545044
- Testing
- JSKN003, Trastuzumab, Pertuzumab
- Volunteers
- 60 people
- Sponsor
- Shanghai JMT-Bio Inc.
Resectable HER2-positive Breast Cancer
A Phase III Study of KN026 in Combination With HB1801 as Adjuvant Therapy for Resectable HER2-Positive Breast Cancer
This is a randomized, controlled, open-label, multicenter, Phase Ⅲ clinical study designed to compare the efficacy and safety of KN026 combined with HB1801 and chemotherapy versus trastuzumab combined with pertuzumab and…
- Trial name
- NCT07441460
- Testing
- KN026, HB1801, Trastuzumab
- Where
- China
- Volunteers
- 1,800 people
- Sponsor
- Shanghai JMT-Bio Inc.
Non-Small Cell Lung Cancer, Small Cell Lung Cancer
SYS6090 Combination Therapy in Advanced Lung Cancer
This is an open-label, multi-cohort, multicenter Phase Ib/II clinical study designed to evaluate the safety, tolerability, and efficacy of SYS6090 injection in combination with chemotherapy or chemotherapy and bevacizumab or…
- Trial name
- NCT07472647
- Testing
- SYS6090 + pemetrexed + platinum-based chemotherapy, SYS6090 + paclitaxel + platinum-based chemotherapy, SYS6090 + docetaxel
- Volunteers
- 596 people
- Sponsor
- Shanghai JMT-Bio Inc.
Healthy Participants
Evaluate the Safety, Tolerability, PK, and PD of JMT206 Injection in Healthy Participants
A This is a single-center, randomized, double-blind, placebo-controlled, dose-escalation Phase I clinical trial. It aims to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of a single administration of…
- Trial name
- NCT07419698
- Testing
- JMT206
- Where
- China
- Volunteers
- 44 people, healthy volunteers welcome
- Sponsor
- Shanghai JMT-Bio Inc.
HER2-positive Colorectal Cancer
JSKN003 Versus Physician Choiced Treatment in Patients With HER2-positive and Advanced Colorectal Cancer Who Had Failed to Respond to Oxaliplatin, 5-Fu, and Irinotecan
The study is being conducted to evaluate the efficacy and safety of JSKN003 Versus Physician Choiced Treatment in Patients With HER2-positive and Advanced Colorectal Cancer Who had Failed to Respond to Oxaliplatin, 5-Fu, and…
- Trial name
- NCT07384377
- Testing
- JSKN003, Physician choiced treatment, include: TAS-102, Regorafenib, Fruquintinib.
- Volunteers
- 123 people
- Sponsor
- Shanghai JMT-Bio Inc.
Advanced Malignant Tumors
First-in-Human Investigation of JMT108 Injection in Participants With Advanced Malignant Tumors
This study is designed as an open-label, multi-center Phase 1 clinical study in participants with advanced malignant tumors to evaluate the safety, tolerability, PK characteristics, and preliminary anti-tumor activity of JMT108…
- Trial name
- NCT06877650
- Testing
- JMT108, Pembrolizumab, Ivonescimab
- Where
- China
- Volunteers
- 436 people
- Sponsor
- Shanghai JMT-Bio Inc.
HER2-positive Gastric Cancer
A Study of KN026-based Combination Therapy in HER2-positive Gastric Cancer
This study is designed to compare the efficacy and safety of KN026 combined chemotherapy with or without Enlonstobart versus Trastuzumab combined chemotherapy with or without Pembrolizumab as first-line treatment in HER2-positive…
- Trial name
- NCT07332533
- Testing
- KN026, Capecitabine, Enlonstobart
- Volunteers
- 490 people
- Sponsor
- Shanghai JMT-Bio Inc.
Hypertriglyceridemia
a Phase 1b/2a Study of JMT202 Injection in Participants With Hypertriglyceridemia
To evaluate the safety and tolerability of multiple subcutaneous injections of JMT202 injection in Chinese participants with hypertriglyceridemia
- Trial name
- phase Ib/Ⅱa st (NCT07140809)
- Testing
- JMT202 injection
- Where
- China
- Volunteers
- 48 people
- Sponsor
- Shanghai JMT-Bio Inc.
Advanced Solid Tumor, Lung Squamous Cell Carcinoma
JMT106 Injection in the Treatment of Advanced Solid Tumors
This study is the first-in-human Phase I study of JMT106 injection, comprising two phases: Dose escalation with backfill and cohort expansion. The planned study population consists of subjects with advanced solid tumors.
- Conditions
- Advanced Solid Tumor, Lung Squamous Cell Carcinoma, Hepatocellular Carcinoma
- Trial name
- NCT07275073
- Testing
- JMT106 Injection
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Shanghai JMT-Bio Inc.
Metastatic Colorectal Cancer (mCRC)
The Study of JMT101 Combined With Irinotecan as a ≥3rd-Line Treatment in Metastatic Colorectal Cancer
This is a randomized, open-label, multicenter, phase III clinical study. The aim is to evaluate the efficacy of JMT101 in combination with irinotecan in the third-line and beyond treatment of Metastatic Colorectal Cancer.
- Trial name
- NCT07134205
- Testing
- JMT101, Irinotecan, Regorafenib
- Volunteers
- 252 people
- Sponsor
- Shanghai JMT-Bio Inc.
Primary Membranous Nephropathy
A Study to Learn More About the Effects and Safety of JMT601 in Adults With Primary Membranous Nephropathy
This study is a multicenter, randomized, controlled, open-label, Phase Ⅱ clinical study to evaluate the efficacy, safety, Pharmacokinetics characteristics, Pharmacodynamics effects, and immunogenicity of JMT601 in participants…
- Trial name
- NCT07029139
- Testing
- JMT601 Injection, Rituximab, Cyclosporin Capsules
- Volunteers
- 156 people
- Sponsor
- Shanghai JMT-Bio Inc.
HER2-positive Gastric Cancer
JSKN003 Combined Treatment of HER2-positive Gastric Cancer
This study is designed to evaluate the safety and efficacy of JSKN003 combination therapy as first-line treatment in HER2-positive unresectable locally advanced or metastatic gastric cancer or resectable gastric cancer.
- Trial name
- NCT06998771
- Testing
- JSKN003, KN026, Capecitabine
- Volunteers
- 153 people
- Sponsor
- Shanghai JMT-Bio Inc.
First-line Treatment of HER2-positive Recurrent or Metastatic Breast Cancer
Efficacy and Safety of KN026 in Combination With HB1801 in the First-line Treatment of Subjects With HER2-positive Recurrent or Metastatic Breast Cancer.
This is a randomized, controlled, open-label, multicenter, phase Ш clinical study designed to compare the efficacy and safety of KN026 in combination with HB1801 to trastuzumab in combination with pertuzumab and docetaxel in the…
- Trial name
- NCT05838066
- Testing
- Recombinant Humanized Bispecific antibody against HER2，KN026, HB1801, Pertuzumab
- Where
- China
- Volunteers
- 880 people
- Sponsor
- Shanghai JMT-Bio Inc.
Non-Small Cell Lung Cancer
A Study to Evaluate the Efficacy and Safety of Glumetinib Combined With Osimertinib Mesylate Versus Platinum-based Doublet Chemotherapy in Non-Small Cell Lung Cancer Patients After Resistance to EGFR-TKIs
The is a randomized, controlled, open-label Phase III clinical study to evaluate the efficacy and safety of glumetinib combined with osimertinib mesylate versus platinum-based doublet chemotherapy in non-small cell lung cancer…
- Trial name
- NCT06829459
- Testing
- Glumetinib, Osimertinib mesylate, Pemetrexed
- Where
- China
- Volunteers
- 350 people
- Sponsor
- Shanghai JMT-Bio Inc.
Recurrent or Metastatic NSCLC Patients With Classical EGFR Mutations Accompanied by MET Amplification or Overexpression
Glumetinib Combined With Osimertinib Treatment for Non-Small Cell Lung Cancer Patients
To evaluate the efficacy and safety of glumetinib combined with osimertinib as the first-line treatment for locally advanced or metastatic NSCLC.
- Trial name
- NCT06908772
- Testing
- Glumetinib Tablets, Osimertinib Mesylate Tablets
- Volunteers
- 390 people
- Sponsor
- Shanghai JMT-Bio Inc.